Vaishali Sanchorawala, MBBS
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MBBS, Seth G.S. Medical College



Expertise includes: AL amyloidosis - clinical trials, treatment; Stem cell transplantation; Myeloma.

Director
Boston University School of Medicine
Amyloidosis Center


Active Staff Hospital Privileges
Boston Medical Center
Medicine




A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium


A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2019 (PI)
Millennium Pharmaceuticals, Inc.


Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc.


An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.


A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2019 (PI)
Celgene Corporation


A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2019 (Co-PI)
PI: Robert W. Simms, MD
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn


Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2018 (Co-PI)
PI: Frederick L. Ruberg, MD
The Brigham and Women's Hospital, Inc. NIH NHLBI
5R01HL130563-02

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno
12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.


Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis
04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.


A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma
03/01/2010 - 03/09/2013 (PI)
Onyx Pharmaceuticals, Inc.


Showing 10 of 13 results. Show All Results

54767414AMY3001
11/17/2017 - 11/17/2020 (PI)
Janssen Research and Development, LLC

Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …
05/11/2015 - 05/31/2020 (PI)
Karmanos Cancer Center

DARA/JANSSEN PI Initiated
03/28/2017 - 03/28/2019 (PI)
Janssen Scientific Affairs LLC

NEOD001-CL002
09/24/2015 - 09/30/2018 (PI)
Prothena Therapeutics Limited

PRONTO - Protocol NEOD001-201
05/13/2016 - 05/31/2018 (PI)
Prothena Therapeutics Limited

Secondary Analysis of Amyloid Repository Data
09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited



Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Ding Y, Francis J, Gautam A, Pelletier L, Sanchorawala V, Quillen K. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection?. Clin Nephrol. 2018 Apr; 89(4):252-259.View Related Profiles. PMID: 29208204.
     
  2. Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. Amyloid. 2018 Mar 08; 1-2.View Related Profiles. PMID: 29516761.
     
  3. Havasi A, Doros G, Sanchorawala V. Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2018 May; 93(5):E129-E132.View Related Profiles. PMID: 29430701.
     
  4. Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018 Mar; 25(1):62-67.View Related Profiles. PMID: 29424556.
     
  5. Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid. 2018 Mar; 25(1):1-7.View Related Profiles. PMID: 29303358.
     
  6. Nguyen VP, Brauneis D, Kaku M, Sloan JM, Sarosiek S, Quillen K, Shelton AC, Sanchorawala V. Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2018 Mar; 53(3):371-373.View Related Profiles. PMID: 29269794.
     
  7. White MK, McCausland KL, Sanchorawala V, Guthrie SD, Bayliss MS. Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Relat Outcome Meas. 2017; 8:157-167. PMID: 29263707.
     
  8. Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biol Blood Marrow Transplant. 2018 Jan; 24(1):127-132.View Related Profiles. PMID: 28865972.
     
  9. Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 01; 18(9):1057-1064.View Related Profiles. PMID: 27965280; DOI: 10.1093/ehjci/jew298;.
     
  10. Sanchorawala V, McCausland KL, White MK, Bayliss MS, Guthrie SD, Lo S, Skinner M. A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. Br J Haematol. 2017 Nov; 179(3):461-470.View Related Profiles. PMID: 28850697.
     
Showing 10 of 119 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 119 publications over 21 distinct years, with a maximum of 12 publications in 2011

YearPublications
19941
19981
19991
20014
20021
20035
20043
20055
20067
20075
20082
20095
20108
201112
201210
20135
20148
201510
201610
201711
20185
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


732 Harrison Ave
Boston MA 02118
Google Map


Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department